Display options
Cite
Farsky PS, White J, Al-Khalidi HR, et al. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2021;doi: 10.1016/j.jtcvs.2020.12.094.
Farsky, P. S., White, J., Al-Khalidi, H. R., Sueta, C. A., Rouleau, J. L., Panza, J. A., Velazquez, E. J., O'Connor, C. M. (2021). Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. The Journal of thoracic and cardiovascular surgery, . https://doi.org/10.1016/j.jtcvs.2020.12.094
Farsky, Pedro S, et al. "Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy." The Journal of thoracic and cardiovascular surgery vol. (2021). doi: https://doi.org/10.1016/j.jtcvs.2020.12.094
Farsky PS, White J, Al-Khalidi HR, Sueta CA, Rouleau JL, Panza JA, Velazquez EJ, O'Connor CM. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2021 Jan 07; doi: 10.1016/j.jtcvs.2020.12.094. Epub 2021 Jan 07. PMID: 33610365; PMCID: PMC8260609.
Copy Download .nbib Format: NLM
Share it on

J Thorac Cardiovasc Surg. 2021 Jan 07; doi: 10.1016/j.jtcvs.2020.12.094. Epub 2021 Jan 07.

Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy.

The Journal of thoracic and cardiovascular surgery

Pedro S Farsky, Jennifer White, Hussein R Al-Khalidi, Carla A Sueta, Jean L Rouleau, Julio A Panza, Eric J Velazquez, Christopher M O'Connor,

Affiliations

  1. Instituto Dante Pazzanese de Cardiologia and Hospital Israelita Albert Einstein, Sao Paulo, Brazil. Electronic address: [email protected].
  2. Duke Clinical Research Institute and Department of Biostatics and Bioinformatics, Duke University School of Medicine, Durham, NC.
  3. Division of Cardiology, University of North Carolina, Chapel Hill, NC.
  4. Department of Medicine, Montréal Heart Institute, Université de Montréal, Montréal, Quebec, Canada.
  5. Westchester Medical Center and New York Medical College, Valhalla, NY.
  6. Department of Medicine, Yale University, New Haven, Conn.
  7. Inova Heart and Vascular Institute, Fairfax, Va.

PMID: 33610365 PMCID: PMC8260609 DOI: 10.1016/j.jtcvs.2020.12.094

Abstract

OBJECTIVES: Optimal medical therapy in patients with heart failure and coronary artery disease is associated with improved outcomes. However, whether this association is influenced by the performance of coronary artery bypass grafting is less well established. Thus, the aim of this study was to determine the possible relationship between coronary artery bypass grafting and optimal medical therapy and its effect on the outcomes of patients with ischemic cardiomyopathy.

METHODS: The Surgical Treatment for Ischemic Heart Failure trial randomized 1212 patients with coronary artery disease and left ventricular ejection fraction 35% or less to coronary artery bypass grafting with medical therapy or medical therapy alone with a median follow-up over 9.8 years. For the purpose of this study, optimal medical therapy was collected at baseline and 4 months, and defined as the combination of 4 drugs: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, beta-blocker, statin, and 1 antiplatelet drug.

RESULTS: At baseline and 4 months, 58.7% and 73.3% of patients were receiving optimal medical therapy, respectively. These patients had no differences in important parameters such as left ventricular ejection fraction and left ventricular volumes. In a multivariable Cox model, optimal medical therapy at baseline was associated with a lower all-cause mortality (hazard ratio, 0.78; 95% confidence interval, 0.66-0.91; P = .001). When landmarked at 4 months, optimal medical therapy was also associated with a lower all-cause mortality (hazard ratio, 0.82; 95% confidence interval, 0.62-0.99; P = .04). There was no interaction between the benefit of optimal medical therapy and treatment allocation.

CONCLUSIONS: Optimal medical therapy was associated with improved long-term survival and lower cardiovascular mortality in patients with ischemic cardiomyopathy and should be strongly recommended.

Copyright © 2021 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Keywords: coronary artery bypass grafting; coronary artery disease; drug therapy; heart failure; heart failure with reduced ejection fraction; treatment outcome

References

  1. Circulation. 2004 Oct 26;110(17):2618-26 - PubMed
  2. Am J Med. 2013 Aug;126(8):693-700.e1 - PubMed
  3. Clin Cardiol. 2012 Apr;35(4):255-6 - PubMed
  4. J Am Coll Cardiol. 2013 Jan 22;61(3):295-301 - PubMed
  5. JAMA. 2013 May 22;309(20):2105-6 - PubMed
  6. Circulation. 2009 Jun 16;119(23):3028-35 - PubMed
  7. N Engl J Med. 2011 Apr 28;364(17):1607-16 - PubMed
  8. J Thorac Cardiovasc Surg. 2007 Oct;134(4):932-8 - PubMed
  9. Circulation. 2013 Oct 15;128(16):e240-327 - PubMed
  10. Circulation. 2015 Oct 6;132(14):1347-53 - PubMed
  11. N Engl J Med. 1985 Jun 27;312(26):1665-71 - PubMed
  12. J Am Coll Cardiol. 2018 Feb 13;71(6):591-602 - PubMed
  13. N Engl J Med. 2009 Mar 5;360(10):961-72 - PubMed
  14. J Thorac Cardiovasc Surg. 2007 Dec;134(6):1540-7 - PubMed
  15. Circulation. 2016 Oct 25;134(17):1238-1246 - PubMed
  16. Circulation. 2006 Jan 17;113(2):203-12 - PubMed
  17. Am Heart J. 2004 Jun;147(6):1047-53 - PubMed
  18. N Engl J Med. 2016 Apr 21;374(16):1511-20 - PubMed
  19. J Am Coll Cardiol. 2005 Jan 18;45(2):177-84 - PubMed
  20. J Am Coll Cardiol. 2018 Jul 24;72(4):351-366 - PubMed
  21. J Am Coll Cardiol. 2016 Sep 6;68(10):985-95 - PubMed
  22. Circulation. 2015 Apr 7;131(14):1269-77 - PubMed

Publication Types

Grant support